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International Committee on 
Harmonis[z]ation of Technical 
Requirements for Registration of 
Pharmaceuticals for Human Use 
(ICH) 
 
Sarah Fowler-Dixon, PhD 
Education Specialist  
Washington University in St. Louis 
2006 
ICH 
Project that brought together the regulatory 
authorities of three regions  
European Union 
 





   and experts from the pharmaceutical industry to 
discuss scientific and technical aspects of 
product registration. 
SIX FOUNDER MEMBERS of ICH 
European Commission (EC) 
European Federation of Pharmaceutical 
Industries’ Associations  (EFPIA) 
Ministry of Health, Labor and Welfare (MHLW) 
Japanese Pharmaceutical Manufacturers 
Association (JPMA)  
Food & Drug Administration (FDA) 




  To  harmonize:  
interpretation and application of technical 
guidelines and requirements for product 
registration  
 
to reduce or obviate duplicate testing 
during the research and development 
of new medicines. 
 
OVERALL OBJECTIVES 
More economical use of human, animal and 
material resources 
 
Elimination of unnecessary delay in the global 
development. 
 
Make new medicines available while maintaining 
safeguards on quality, safety and efficacy, and 
regulatory obligations to protect public health. 
Part 1 of Harmonization 
Focused on the technical requirements for 
developing and registering products 
containing new drug substances, in these 
regions. 
 
Have developed over 40 guidelines for new 
drug products.  
Part 2 of Harmonization 
Developed a: 
mechanism to harmonize new technical 
requirements resulting from scientific 
progress and developments in innovative 
drug research; 
 
process for updating and supplementing 




Achieved through the development of 
Guidelines 
 
Each Guidance has its own specific 
objectives 
 
Examples from E8 
General Considerations for  
Clinical Trials 
 




Need results of nonclinical investigations 
or previous human or animal studies 
 
Scientific Approach in Design and 
Analysis 
 
Sound scientific principles are needed for 
the design, conduct or analysis of a clinical 
trial. 
– Trials are classified based on objectives 
Development of Methodology 
 
For each type of study, ICH outlines 
considerations relating to the development 
plan for the study 
– E.g. Safety Study 
Dose to be determined by examination of 
nonclinical pharmacokinetic, pharmacological and 
toxicological evaluations 
Early nonclinical studies should support initial 
human dose, safe duration of exposure to the drug, 
and information about the new drug’s physiological 
and toxicological effects 
 
Quality of Investigational Medical 
Products 
 
Outlines drug phases 
 
Addresses special considerations 













Process for Development of New 
ICH Guideline or Recommendation 
1. Consensus building within Expert Working 
Group 
2. Start of Regulatory Action 
3. Regulatory Consultation within the Regions 
4. Adoption of a Tripartite Harmonis[z]ed Text 
(confirm that consultation did not alter text) 




"Quality" Topics, i.e., those relating to chemical and 
pharmaceutical Quality Assurance. 
 
"Safety" Topics, i.e., those relating to in vitro and in 
vivo pre-clinical studies.  
 
"Efficacy" Topics, i.e., those relating to clinical 
studies in human subject.  
              (E6)   Good Clinical Practices  
 
"Multidisciplinary" Topics, i.e., cross-cutting Topics 
which do not fit uniquely into one of the above 
categories. 
– Medical Terminology (MedDRA)  
– Electronic Standards Timing of Pre-clinical 









E6 Guideline for Good Clinical Practice 
 
 
 
 
